The role of CDK4/6 inhibitors in early breast cancer

Breast

Antonio Llombart-Cussac¹  Emilio Alba²  Juan de la Haba-Rodríguez³  Eva Ciruelos⁴  Pablo Tolosa⁴  Joaquín Gavilá⁵  Miguel Gil-Gil⁶  Daniele Candini⁷ 

[1] Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain;Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain;Department of Medical Oncology, Hospital Universitario Reina Sofía, Instituto de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain;Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain;Fundación Instituto Valenciano de Oncología, Valencia, Spain;Institut Català d'Oncologia IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain;Medical Department, Pfizer Oncology, Madrid, Spain;

关键词: Early breast cancer;    Cyclin-dependent kinase 4/6 inhibitors;    Adjuvant therapy;    Palbociclib;    Abemaciclib;   

DOI  :  

来源: DOAJ

【 摘 要 】

The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.

【 授权许可】

Unknown